Fundraising FoxMind Medicine (MindMed)
New York, US · Founded 2019 · British Columbia, Canada corporation · 5 known investors
Find your way into Mind Medicine (MindMed)
Sign up to see every warm intro you have to Mind Medicine (MindMed)
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mind Medicine (MindMed) team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MindMed is a biotech company developing psychedelic-based therapeutics, including a proprietary orally disintegrating LSD tablet (DT120) and an R-enantiomer of MDMA (DT402), to treat brain health disorders such as generalized anxiety disorder, major depressive disorder, PTSD, and autism spectrum disorder. Its work targets patients in the U.S. and remains in clinical/preclinical stages, not yet FDA-approved.
Founders & leadership
Mind Medicine (MindMed) was founded in 2019 by Stephen Hurst, Scott Freeman, JR Rahn, and JAMON ALEXANDER RAHN.
SF
Scott FreemanCo-founder
JR
JR RahnCo-founder
JA
JAMON ALEXANDER RAHNCo-founder
CL
Carrie LiaoExecutiveCarrie Liao is an Executive Officer at Mind Medicine (MindMed) with extensive experience in life sciences and biotech finance, including roles at clinical-stage, manufacturing, and commercial-stage companies. She has served as Chief Accounting Officer at a public biotech company, overseeing SEC reporting, SOX compliance, financial modeling, and IPO readiness, and brings expertise in GAAP and IFRS accounting, FP&A, and finance system implementation.
MR
Mark R. SullivanExecutiveMark Sullivan holds an M.D. and Ph.D. in Philosophy from Vanderbilt University and serves as a Professor of Psychiatry at the University of Washington, where he has been an attending physician at the Center for Pain Relief for 35 years and co-directs behavioral health services. He has authored over 300 peer-reviewed publications focused on the intersection of physical and mental health in chronic illness.
DK
Daniel KarlinExecutive
NR
Nico R ForteNamed on SEC filing
BM
BRIGID MAKESNamed on SEC filing
BL
BRUCE LINTONNamed on SEC filing
Investors · 5
BT Growth Capitallisted by BT Growth CapitalNew York
How we know: BT Growth Capital's portfolio page · Not right? Tell us
Daft Capitallisted by Daft CapitalPalo Alto · $500K – $2Mvia Jon Dishotsky · inferred
How we know: Daft Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$107.2M disclosed across 8 of 10 rounds · 2019–2025
▶$7MraisedMay 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$7MraisedMay 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carrie LiaoExecutive Officer
- Suzanne BruhnDirector
- Carol A. ValloneDirector
- Mark R. SullivanExecutive Officer
- Andreas KrebsDirector
- Matt WileyExecutive Officer
- Robert BarrowDirector, Executive Officer
- Roger CrystalDirector
- David GryskaDirector
- Daniel KarlinExecutive Officer
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Aug 2023
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$75MraisedMar 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$75MraisedMar 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David GryskaDirector
- Schond GreenwayExecutive Officer
- Andreas KrebsDirector
- Carol A. ValloneDirector
- Roger CrystalDirector
- Carrie LiaoExecutive Officer
- Suzanne BruhnDirector
- Mark R. SullivanExecutive Officer
- Miri Halperin WernliExecutive Officer
- Robert BarrowDirector, Executive Officer
- Daniel KarlinExecutive Officer
- Offering amount
- $75M
- Amount sold
- $75M
- Sales commissions
- $4.5M
- Placement agents
- RBC Capital Markets, LLC, Cantor Fitzgerald & Co., Leerlink Partners LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$499.6KraisedJan 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$499.6KraisedJan 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen HurstExecutive Officer, Director
- Jamon Alexander RahnExecutive Officer, Director
- Miriam Halperin WernliExecutive Officer, Director
- Brigid MakesDirector
- Stanley GlickDirector
- Bruce LintonDirector
- Perry DellelceDirector
- Offering amount
- $826.1K
- Amount sold
- $499.6K
- First sale
- Jan 2021
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$78.3KraisedDec 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$78.3KraisedDec 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Perry DellelceDirector
- Bruce LintonDirector
- Stanley GlickDirector
- Brigid MakesDirector
- Miriam Halperin WernliExecutive Officer, Director
- Jamon Alexander RahnExecutive Officer, Director
- Stephen HurstExecutive Officer, Director
- Offering amount
- $128.7K
- Amount sold
- $78.3K
- First sale
- Dec 2020
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$247.7KraisedNov 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$247.7KraisedNov 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bruce LintonDirector
- Perry DellelceDirector
- Stanley GlickDirector
- Miriam Halperin WernliExecutive Officer, Director
- Jamon Alexander RahnExecutive Officer, Director
- Stephen HurstExecutive Officer, Director
- Brigid MakesDirector
- Offering amount
- $412.8K
- Amount sold
- $247.7K
- First sale
- Oct 2020
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$468.2KraisedJun 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$468.2KraisedJun 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- BRIGID MAKESDirector
- BRUCE LINTONDirector
- PERRY DELLELCEDirector
- STEPHEN HURSTExecutive Officer, Director
- STANLEY GLICKDirector
- JAMON ALEXANDER RAHNExecutive Officer, Director
- MIRIAM HALPERIN WERNLIDirector
- Offering amount
- $468.2K
- Amount sold
- $468.2K
- First sale
- May 2020
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$19.3MraisedMar 2020 · 47 investors · OtherRule 506(b)
▶$19.3MraisedMar 2020 · 47 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Scott FreemanExecutive Officer
- Brigid MakesDirector
- Bruce LintonDirector
- Don GehlertExecutive Officer
- Stanley GlickDirector
- Perry DellelceDirector
- Stephen HurstExecutive Officer, Director, Promoter
- Jamon Alexander RahnExecutive Officer, Director
- Offering amount
- $19.3M
- Amount sold
- $19.3M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4.6MraisedSep 2019 · 50 investors · OtherRule 506(b)
▶$4.6MraisedSep 2019 · 50 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Stephen HurstExecutive Officer, Director, Promoter
- Nico R ForteExecutive Officer
- Scott FreemanExecutive Officer
- JR RahnDirector
- Offering amount
- $5M
- Amount sold
- $4.6M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Mind Medicine (MindMed) do?
- MindMed is a biotech company developing psychedelic-based therapeutics, including a proprietary orally disintegrating LSD tablet (DT120) and an R-enantiomer of MDMA (DT402), to treat brain health disorders such as generalized anxiety disorder, major depressive disorder, PTSD, and autism spectrum disorder. Its work targets patients in the U.S. and remains in clinical/preclinical stages, not yet FDA-approved.
- Who founded Mind Medicine (MindMed)?
- Mind Medicine (MindMed) was founded by Stephen Hurst, Scott Freeman, JR Rahn, JAMON ALEXANDER RAHN in 2019.
- Who are Mind Medicine (MindMed)'s investors?
- Mind Medicine (MindMed)'s investors include Bailey Venture Partners, BT Growth Capital, Daft Capital, K2 HealthVentures, Noetic.
- How much funding has Mind Medicine (MindMed) raised?
- Mind Medicine (MindMed) has disclosed $107.2M raised across 8 of its 10 known rounds.
- Where is Mind Medicine (MindMed) headquartered?
- Mind Medicine (MindMed) is headquartered in New York, US.